AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37653830 — intervention group
Group type: COMPARATOR
Intervention: No preanesthesia assessment clinic (non-PAC)
Number of subjects: 30351
Study 37654065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumipulse assay for plasma pTau181
Number of subjects: 0
Study 37654065 — intervention group
Group type: COMPARATOR
Intervention: Simoa assay for plasma pTau181
Number of subjects: 0
Study 37654656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (TC)
Number of subjects: 12
Study 37654659 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive physical plasma (NIPP) treatment
Number of subjects: 63
Study 37654659 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 63
Study 37654667 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary transcutaneous electrical stimulation (TESLA)
Number of subjects: 56
Study 37654667 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study 37654670 — intervention group
Group type: EXPERIMENTAL
Intervention: MaaT013 (pooled allogeneic faecal microbiota)
Number of subjects: 24
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody treatment
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids therapy for mild/severe cases
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 1796
Study 37654668 — intervention group
Group type: COMPARATOR
Intervention: Post-COVID-19 syndrome (PCS)
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptoms during acute infection
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal complications during acute infection
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 1796
Study 37654668 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with monoclonal Ab
Number of subjects: 1796
Study 37654895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) + anti-PD-1 treatment (sintilimab)
Number of subjects: 39
Study 37654895 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 treatment (sintilimab) alone
Number of subjects: 39
Study 37654895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP)
Number of subjects: 39
Study 37654895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of APAP and anti-PD-1 treatment
Number of subjects: 39
Study 37655106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (13 patients)
Number of subjects: 48
Study 37655106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (26 patients)
Number of subjects: 48
Study 37655106 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy (9 patients)
Number of subjects: 48
Study 37655205 — intervention group
Group type: EXPERIMENTAL
Intervention: selpercatinib treatment
Number of subjects: 77
Study 37655258 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in addition to optimal medical therapy
Number of subjects: 0
Study 37655258 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study 37655691 — intervention group
Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 0
Study 37655691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37656041 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional RECIST assessment
Number of subjects: 0
Study 37656041 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric assessment of RECIST target lesions
Number of subjects: 0
Study 37656067 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI protocol (3 T/T)
Number of subjects: 10
Study 37656067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton multiparametric MRI
Number of subjects: 10
Study 37656067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium MRI
Number of subjects: 10
Study 37656180 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Brexpiprazole
Number of subjects: 0
Study 37656180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37656252 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) + walking promotion
Number of subjects: 31
Study 37656252 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational materials on general exercise)
Number of subjects: 31
Study 37656263 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Number of subjects: 174
Study 37656263 — intervention group
Group type: COMPARATOR
Intervention: Historical standard of care (SCA)
Number of subjects: 174
Study 37656286 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 25
Study 37656286 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM
Number of subjects: 25
Study 37656286 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 37656308 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-CCP intervention (n=20)
Number of subjects: 40
Study 37656308 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (n=20)
Number of subjects: 40
Study 37656413 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills (CDDP) - 20 tablets before pPCI and 10 tablets 3 times daily after pPCI
Number of subjects: 268
Study 37656413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 37656413 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills (CDDP)
Number of subjects: 268
Study 37656441 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab with/without corticosteroids
Number of subjects: 102
Study 37656441 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid monotherapy
Number of subjects: 102
Study 37656441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL6-directed therapy (siltuximab or tocilizumab)
Number of subjects: 102
Study 37656441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 102
Study 37656456 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized EHR-based recruitment model
Number of subjects: 13523
Study 37656493 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective SMS text messages reminding users about feeling good after exercise (40% probability)
Number of subjects: 120
Study 37656493 — intervention group
Group type: COMPARATOR
Intervention: Control reminders (30% probability)
Number of subjects: 120
Study 37656493 — intervention group
Group type: COMPARATOR
Intervention: No message (30% probability)
Number of subjects: 120
Study 37656493 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective SMS text messages requiring a response
Number of subjects: 120
Study 37656493 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective SMS text messages in a read-only format
Number of subjects: 120
Study 37656500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported HIV risk assessment tool with tailored feedback (group 1)
Number of subjects: 9280
Study 37656500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported HIV risk assessment without feedback (group 2)
Number of subjects: 9280
Study 37656500 — intervention group
Group type: COMPARATOR
Intervention: Government-recommended HIV education materials (control)
Number of subjects: 9280
Study 37656683 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet on postoperative day 0
Number of subjects: 105
Study 37656683 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet on postoperative day 0
Number of subjects: 105
Study 37656890 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (3,871 participants)
Number of subjects: 7835
Study 37656890 — intervention group
Group type: COMPARATOR
Intervention: Control group (3,964 participants)
Number of subjects: 7835
Study 37656930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians
Number of subjects: 173
Study 37656930 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 173
Study 37656948 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery (NACT-S), n = 314
Number of subjects: 626
Study 37656948 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (CCRT), n = 312
Number of subjects: 626
Study 37656991 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during periods with an AHRE burden <1 h/day
Number of subjects: 568
Study 37656991 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during periods with an AHRE burden ≥20 h/day
Number of subjects: 568
Study 37656991 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during IN-alert periods
Number of subjects: 568
Study 37656991 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during OUT-of-alert periods
Number of subjects: 568
Study 37656991 — intervention group
Group type: COMPARATOR
Intervention: Matched non-AHRE group during IN-alert periods
Number of subjects: 568
Study 37656991 — intervention group
Group type: COMPARATOR
Intervention: Matched non-AHRE group during OUT-of-alert periods
Number of subjects: 568
Study 37656991 — intervention group
Group type: COMPARATOR
Intervention: Matched non-AHRE group
Number of subjects: 568
Study 37657154 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated FDG PET/CT image analysis
Number of subjects: 8
Study 37657154 — intervention group
Group type: COMPARATOR
Intervention: Lesion segmentation
Number of subjects: 8
Study 37657154 — intervention group
Group type: COMPARATOR
Intervention: International Myeloma Working Group (IMWG) response criteria
Number of subjects: 8
Study 37657279 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Services (EIS) - NAVIGATE
Number of subjects: 404
Study 37657279 — intervention group
Group type: COMPARATOR
Intervention: Usual Community Care (CC)
Number of subjects: 404
Study 37657460 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields therapy with standard systemic therapy (investigator's choice of immune checkpoint inhibitor or docetaxel)
Number of subjects: 276
Study 37657460 — intervention group
Group type: COMPARATOR
Intervention: Standard systemic therapy alone
Number of subjects: 276
Study 37657460 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields therapy with standard systemic therapy
Number of subjects: 276
Study 37657460 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields therapy-related adverse events
Number of subjects: 276
Study 37657460 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 276
Study 37657461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal screening
Number of subjects: 202562
Study 37657461 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 202562
Study 37657462 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant plus palbociclib
Number of subjects: 221
Study 37657462 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole plus palbociclib
Number of subjects: 221
Study 37657463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vectors expressing HSV1-TK and Flt3L, administered via injections into the tumor bed after maximal safe resection, with six escalating doses starting from 1×10 (exact dosage not specified).
Number of subjects: 18
Study 37657463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral vectors expressing HSV1-TK and Flt3L (combined treatment).
Number of subjects: 18
Study 37657522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.125 M L-glutamic acid at 1.65 mL/kg/h for 150 min before reperfusion
Number of subjects: 451
Study 37657522 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 451
Study 37657522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.125 M L-glutamic acid
Number of subjects: 451
Study 37657525 — intervention group
Group type: EXPERIMENTAL
Intervention: TwHF+rhTNFR-Fc
Number of subjects: 504
Study 37657525 — intervention group
Group type: COMPARATOR
Intervention: MTX+rhTNFR-Fc
Number of subjects: 504
Study 37657525 — intervention group
Group type: COMPARATOR
Intervention: TwHF monotherapy
Number of subjects: 504
Study 37657525 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 504
Study 37657523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose 8 g/d (plus 2 g/d maltodextrin)
Number of subjects: 92
Study 37657523 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose 8 g/d plus 2'fucosyllactose (2 g/d)
Number of subjects: 92
Study 37657523 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'fucosyllactose 2 g/d (plus 8 g/d maltodextrin)
Number of subjects: 92
Study 37657523 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin 10 g/d
Number of subjects: 92
Study 37657559 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR (300 mg × 2, 100 mg × 4)
Number of subjects: 916
Study 37657559 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR (300 mg × 6)
Number of subjects: 916
Study 37657559 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR (for early nonresponders)
Number of subjects: 916
Study 37657559 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR
Number of subjects: 916
Study 37657559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study 37657593 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress perfusion cardiovascular MRI (CMR) imaging
Number of subjects: 0
Study 37657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PCI implantation of an IMPELLA
Number of subjects: 0
Study 37657594 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 0
Study 37657624 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients with adulthood adversity (AA)
Number of subjects: 170
Study 37657624 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 170
Study 37657624 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 170
Study 37657646 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior GDM
Number of subjects: 1808
Study 37657646 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangladesh
Number of subjects: 1808
Study 37657646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sri Lanka
Number of subjects: 1808
Study 37657646 — intervention group
Group type: EXPERIMENTAL
Intervention: India
Number of subjects: 1808
Study 37657646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age, lower education status, higher prior pregnancy count, prior history of GDM, family history of DM, postpartum overweight/obese status
Number of subjects: 1808
Study 37657768 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan (endothelin receptor antagonist)
Number of subjects: 0
Study 37657768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37657939 — intervention group
Group type: EXPERIMENTAL
Intervention: Neflamapimod 40 mg three times daily (TID)
Number of subjects: 85
Study 37657939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 37658043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to digital imagery-competing task intervention (weeks 1-4)
Number of subjects: 86
Study 37658043 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to digital imagery-competing task intervention (weeks 5-8)
Number of subjects: 86
Study 37658043 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to digital imagery-competing task intervention (after crossover)
Number of subjects: 86
Study 37658043 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to digital imagery-competing task intervention
Number of subjects: 86
Study 37658083 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg)
Number of subjects: 20
Study 37658083 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of functional adaptive immunity
Number of subjects: 20
Study 37658205 — intervention group
Group type: EXPERIMENTAL
Intervention: Equecabtagene autoleucel
Number of subjects: 0
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 7105
Study 37658223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 7105
Study 37658223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7105
Study 37658272 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 146
Study 37658272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MammaPrint and BluePrint
Number of subjects: 146
Study 37658272 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint High Risk tumors
Number of subjects: 146
Study 37658272 — intervention group
Group type: EXPERIMENTAL
Intervention: BluePrint (gLuminal B, gHER2, gBasal)
Number of subjects: 146
Study 37658272 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT (Neoadjuvant Chemotherapy)
Number of subjects: 146
Study 37658305 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HIV viral load test
Number of subjects: 0
Study 37658305 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) HIV screening tests
Number of subjects: 0
Study 37658323 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhoods with higher disadvantage or disorder
Number of subjects: 288
Study 37658323 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood disadvantage
Number of subjects: 288
Study 37658323 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social environment measures of chronic stress exposure
Number of subjects: 288
Study 37658341 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing technique and common risk factor approach intervention
Number of subjects: 0
Study 37658341 — intervention group
Group type: COMPARATOR
Intervention: Standard care information (Control)
Number of subjects: 0
Study 37658342 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen plug soaked in blood
Number of subjects: 24
Study 37658342 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix Grafton
Number of subjects: 24
Study 37658342 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate mixture of 2/3 autogenous bone chips and 1/3 deproteinized bovine bone mineral MinerOss X
Number of subjects: 24
Study 37658342 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 24
Study 37658365 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 688
Study 37658365 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin S
Number of subjects: 688
Study 37658365 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron imbalance
Number of subjects: 688
Study 37658365 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall undernutrition
Number of subjects: 688
Study 37658373 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to Addiction Recovery (R2AR) instrument
Number of subjects: 0
Study 37658373 — intervention group
Group type: EXPERIMENTAL
Intervention: R2AR instrument
Number of subjects: 0
Study 37658397 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative services (Pal-Care) delivered by community health workers (CHWs)
Number of subjects: 90
Study 37658397 — intervention group
Group type: COMPARATOR
Intervention: Usual cancer-center-based palliative services
Number of subjects: 90
Study 37658464 — intervention group
Group type: EXPERIMENTAL
Intervention: NDT-Tango (neurologic dance training through partnered Adapted Tango) for 8 weeks
Number of subjects: 0
Study 37658464 — intervention group
Group type: COMPARATOR
Intervention: Home exercise (HEX) intervention for 8 weeks
Number of subjects: 0
Study 37658468 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cell (ASC) injection into the submandibular glands (n=60)
Number of subjects: 120
Study 37658468 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (CryoStor10, n=60)
Number of subjects: 120
Study 37658603 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-1-targeting CRISPR formulation
Number of subjects: 3
Study 37658755 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education
Number of subjects: 90
Study 37658755 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 90
Study 37658997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 0
Study 37658997 — intervention group
Group type: EXPERIMENTAL
Intervention: S/N ratios
Number of subjects: 0
Study 37658997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging electrochemiluminescence (ECL) ADA assays
Number of subjects: 0
Study 37658997 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-bococizumab antibodies
Number of subjects: 0
Study 37659025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (adjuvant therapy)
Number of subjects: 0
Study 37659025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37659283 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg per day for one week
Number of subjects: 16
Study 37659283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16